Law Office Of Brodsky & Smith, LLC Announces Investigation Of MAP Pharmaceuticals, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of MAP Pharmaceuticals, Inc. (“MAP” or the “Company”) (Nasdaq: MAPP) relating to the proposed acquisition by Allergan, Inc. (“Allergan”).

Under the terms of the transaction, MAP shareholders will receive only $25.00 in cash for each share of MAP stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of MAP for not acting in the Company’s shareholders' best interests in connection with the sale process to Allergan. MAP is expected to receive a decision on its inhalable migraine treatment Levadex by the Food and Drug Administration before mid-April. It has been reported that the global migraine drug market will reach $5.8 billion by 2021.

If you own shares of MAP stock and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at investorrelations@brodsky-smith.com visiting http://brodsky-smith.com/530-mapp-map-pharmaceuticals-inc.html, by calling toll free 877-LEGAL-90.

Copyright Business Wire 2010

If you liked this article you might like

Allergan's Healthy Prospects

Cramer's 6 Stocks in 60 Seconds: SNV TXN UL CREE MAPP KBH (Update 1)

2013 FDA Drug Approval Decision Calendar

Biotech Stock Mailbag: Aveo, Anthera, Amarin, MAP Pharma

MAP Pharma's Awkward FDA Silence